Back to results
US 12,435,101 B2Granted
Isochroman compound
AssigneeZhejiang Yangli Pharmaceutical Technology Co., Ltd.
InventorsZhe Cai, Fei Sun, Charles Z. Ding, Shuhui Chen
Life of this patent
Estimating the term…
Abstract
Provided is an isochroman compound represented by formula (I), or a pharmaceutically acceptable salt thereof, which is used as an aldo-keto reductase (AKR1C3) inhibitor for the treatment of liver cancer.
Claims14
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof,
- wherein T is N or CH;
- R1 and R2 are each independently H, F, Cl, Br, I, or C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted by 1, 2, or 3 Ra;
- each Ra is independently F, Cl, Br, I, —CN, —OH or —NH2;
- R3 and R4 are each independently H, F, Cl, Br, I, CN, C1-3 alkyl, C1-3 alkoxy,
- wherein the C1-3 alkyl is optionally substituted by 1, 2 or 3 Re;
- Rb and Rc are each independently H, —CH3, —CH2CH3, —(CH2)2CH3 or —CH(CH3)2;
- Rd is —CH3, —CH2CH3, —(CH2)2CH3 or —CH(CH3)2;
- each Re is independently F, Cl, Br, I, —CN, —OH or —NH2.
5 more elements
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.